A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyStructure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesPhase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancerIdentification of a conserved anti-apoptotic protein that modulates the mitochondrial apoptosis pathway.UCN-01 induces S and G2/M cell cycle arrest through the p53/p21(waf1) or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines.A small-molecule screening strategy to identify suppressors of statin myopathy.Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitorsA phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.Mitosis-targeted anti-cancer therapies: where they stand.An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
P2860
Q26745686-336DFCB6-E164-48DD-9A47-6F8C27E269D9Q26864870-032439F6-0B38-493F-90A1-C7AFA1EFB67BQ33400687-F4C2CA58-012F-4838-B586-D8B58C3A5834Q34043049-D635C2D0-08E7-47A7-A51A-C52651F61694Q34640744-41FF3704-B747-4C26-A67F-68DB1B0C1EBDQ35223789-C5904F0C-3D3A-414F-A271-598761C56072Q35621123-739447E6-78BC-49C4-92E4-8E95336935B2Q35751850-D06E8346-C1DA-4EEA-882C-2643B31D0E99Q36048547-399F5C78-5E6C-4F40-8C79-B899F0971797Q38053055-6CBB9209-3660-42B5-BD31-610E5A89ACAEQ45327842-8E28445B-7755-4EB3-B135-61D40860E412Q54316808-6DBF2CA3-F143-4350-AD57-620BADD62C42
P2860
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A phase I trial of UCN-01 and ...... ry solid tumors and lymphomas.
@ast
A phase I trial of UCN-01 and ...... ry solid tumors and lymphomas.
@en
type
label
A phase I trial of UCN-01 and ...... ry solid tumors and lymphomas.
@ast
A phase I trial of UCN-01 and ...... ry solid tumors and lymphomas.
@en
prefLabel
A phase I trial of UCN-01 and ...... ry solid tumors and lymphomas.
@ast
A phase I trial of UCN-01 and ...... ry solid tumors and lymphomas.
@en
P2093
P2860
P1476
A phase I trial of UCN-01 and ...... ry solid tumors and lymphomas.
@en
P2093
Anthony J Murgo
Barbara A Conley
Edward A Sausville
Erin R Gardner
Giovanni Melillo
James H Doroshow
Janet Dancey
Martin E Gutierrez
Shivaani Kummar
William D Figg
P2860
P2888
P304
P356
10.1007/S00280-009-1154-Y
P577
2009-11-06T00:00:00Z
P5875
P6179
1039019559